Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of 5-HT1A Receptor Agonists: Estimation of in Vivo Affinity and Intrinsic Efficacy on Body Temperature in Rats

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2004-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/JPET.103.059030PMID 14718609
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalogram Effects of GABAA Receptor Modulators: In Vitro-in Vivo Correlations

  2003cited by this paper
• Mechanism-Based Pharmacodynamic Modeling of the Interaction of Midazolam, Bretazenil, and Zolpidem with Ethanol

  2002cited by this paper
• A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia.

  2002cited by this paper
• Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan.

  2002influential reference
• Neuroactive Steroids Differ in Potency but Not in Intrinsic Efficacy at the GABAA Receptor in Vivo

  2002cited by this paper
• Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats

  2002influential reference
• Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier.

  2001cited by this paper
• A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia.

  2001influential reference
• Pharmacokinetic-Pharmacodynamic Analysis of the EEG Effect of Alfentanil in Rats Followingβ-Funaltrexamine-Induced μOpioid Receptor “Knockdown”In Vivo

  2000cited by this paper
• Enantioselective high-performance liquid chromatographic analysis of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin. Application to a pharmacokinetic-pharmacodynamic study in rats.

  2000cited by this paper
• Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor "knockdown" in vivo.

  2000cited by this paper
• 5‐HT1A receptor agonist‐antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems

  2000cited by this paper
• Enantioselective high-performance liquid chromatographic analysis of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin. Application to a pharmacokinetic-pharmacodynamic study in rats.

  2000cited by this paper
• Correlation between low/high affinity ratios for 5-HT(1A) receptors and intrinsic activity.

  1999cited by this paper
• Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam.

  1999cited by this paper
• Characterization of the Pharmacodynamic Interaction between Parent Drug and Active Metabolite In Vivo: Midazolam and α-OH-Midazolam

  1999cited by this paper
• Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo.

  1999cited by this paper
• Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor.

  1998cited by this paper
• Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors.

  1997cited by this paper
• On the reliability of affinity and efficacy estimates obtained by direct operational model fitting of agonist concentration-effect curves following irreversible receptor inactivation.

  1997cited by this paper
• To What Extent Can Binding Studies Allow the Quantification of Affinity and Efficacy?

  1997cited by this paper
• Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling.

  1997cited by this paper
• Use of an antagonist for estimating the degree of agonist stimulation during physiological release.

  1995cited by this paper
• 5-HT1A receptor agonists: recent developments and controversial issues

  1995cited by this paper
• 5-HT1A receptor agonists: recent developments and controversial issues.

  1995cited by this paper
• Comparison of four basic models of indirect pharmacodynamic responses

  1993cited by this paper
• Activity of serotonin (5-HT) receptor agonists, partial agonists and antagonists at cloned human 5-HT1A receptors that are negatively coupled to adenylate cyclase in permanently transfected HeLa cells.

  1993cited by this paper
• Nonlinear mixed effects models for repeated measures data.

  1990cited by this paper
• Estimation of agonist affinity and efficacy by direct, operational model-fitting.

  1990cited by this paper
• Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine1A receptor gene.

  1990cited by this paper
• Statistical Inference

  1990cited by this paper
• The discovery and development of buspirone: A new approach to the treatment of anxiety

  1990cited by this paper
• Operational models of pharmacological agonism

  1983influential reference
• A new look at the statistical model identification

  1974cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• Modeling and Simulation in the Translational Pharmacology of CNS Drugs

  2019cites this paper
• Novel Object Recognition Test in Rodents:: Which Roles for Serotonin Receptors?

  2018cites this paper
• 5-HT1a Receptor Involvement in Temporal Memory and the Response to Temporal Ambiguity

  2018cites this paper
• Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.

  2017cites this paper
• Systems pharmacology - Towards the modeling of network interactions.

  2016influential citation
• Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice

  2016cites this paper
• Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models

  2015cites this paper
• The Emerging Discipline of Quantitative Systems Pharmacology

  2015cites this paper
• Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability

  2014cites this paper
• Cross-species scaling of cardiovascular safety pharmacology using PKPD modelling and simulation

  2013cites this paper
• Integration of PBPK and Pharmacodynamics

  2012cites this paper
• Mechanism-based PK–PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans

  2012cites this paper
• Facilitation of hypothermia by quinpirole and 8-OH-DPAT in a rat model of cardiac arrest.

  2012cites this paper
• Disease Progression Analysis: Towards Mechanism-Based Models

  2011cites this paper
• The Role of the Blood-Brain Barrier

  2009cites this paper
• Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.

  2009cites this paper
• Target site occupancy: emerging generalizations from clinical and preclinical studies.

  2009cites this paper
• Discovery DMPK: changing paradigms in the eighties, nineties and noughties

  2009cites this paper
• Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

  2008cites this paper
• A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.

  2008cites this paper
• IDENTIFICATION OF THE OPERATIONAL MODEL OF AGONISM FOR THE EEG EFFECTS OF OPIOIDS: ESTIMATION OF THE IN VIVO AFFINITY AND INTRINSIC EFFICACY AT THE -OPIOID RECEPTOR

  2007cites this paper
• Animal-to-Human Extrapolation of the Pharmacokinetic and Pharmacodynamic Properties of Buprenorphine

  2007cites this paper
• Allometric Scaling of Pharmacodynamic Responses: Application to 5-Ht1A Receptor Mediated Responses from Rat to Man

  2007cites this paper
• Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.

  2007cites this paper
• Pharmacokinetic‐pharmacodynamic modelling of S(−)‐atenolol in rats: reduction of isoprenaline‐induced tachycardia as a continuous pharmacodynamic endpoint

  2007cites this paper
• The Why and How of Absorption, Distribution, Metabolism, Excretion, and Toxicity Research

  2007cites this paper
• Differential effects of 5-HT 4 receptor agonists at gastric versus cardiac receptors : an operational framework to explain and quantify organ specific behaviour

  2006cites this paper
• Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory-Depressant Effect of Buprenorphine and Fentanyl in Rats

  2006cites this paper
• Differential Effects of 5-Hydroxytryptamine4 Receptor Agonists at Gastric versus Cardiac Receptors: An Operational Framework to Explain and Quantify Organ-Specific Behavior

  2006cites this paper
• In vitro prediction of brain penetration – a case for free thinking?

  2006cites this paper
• Mechanism-based Pharmacokinetic–Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine in Healthy Volunteers

  2006cites this paper
• Modeling Drug- and System-Related Changes in Body Temperature: Application to Clomethiazole-Induced Hypothermia, Long-Lasting Tolerance Development, and Circadian Rhythm in Rats

  2006cites this paper
• Involvement of serotoninergic receptors in the anteroventral preoptic region on hypoxia-induced hypothermia.

  2005cites this paper
• Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics

  2005cites this paper
• Fromin vivotoin vitro/in silicoADME: progress and challenges

  2005cites this paper
• Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers

  2005cites this paper
• From in vivo to in vitro/in silico ADME: progress and challenges

  2005cites this paper
• Mechanism-Based Pharmacodynamic Modeling for Prediction of Exposure Response

  2004cites this paper